NCT03293992View on ClinicalTrials.gov

A Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7058584 Following 7 Days of Instillation of Eye Drops in Patients With Primary Open Angle Glaucoma or Ocular Hypertension

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

October 10, 2017

Primary Completion Date

December 15, 2017

Study Completion Date

December 21, 2017

Conditions
Glaucoma, Open-angleOcular Hypertension
Interventions
DRUG

0.01% RO7058584

Once daily morning administration for 7 days

DRUG

0.1% RO7058584

Once daily morning administration for 7 days

DRUG

1% RO7058584

Once daily morning administration for 7 days

DRUG

Matching Placebo

Once daily morning administration for 7 days

DRUG

Latanoprost 0.005%

Once daily morning or evening dosing

Trial Locations (8)

30076

Coastal Research Associates, Roswell

30260

Eye Care Centers Management, Inc. (Clayton Eye Center), Morrow

78731

Texan Eye/Keystone Research, Austin

80045

Rocky Mountain Lions Eye Inst, Aurora

85225

Arizona Eye Center, Chandler

90301

United Med Res Inst, Inglewood

90701

Sall Research Medical Center, Artesia

92663

Eye research foundation, Newport Beach

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT03293992 - A Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7058584 Following 7 Days of Instillation of Eye Drops in Patients With Primary Open Angle Glaucoma or Ocular Hypertension | Biotech Hunter | Biotech Hunter